Newron Pharmaceuticals S.p.A. Logo

Newron Pharmaceuticals S.p.A.

Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.

NWRN | SW

Overview

Corporate Details

ISIN(s):
IT0004147952
LEI:
8156002F8C11F80A9740
Country:
Italy
Address:
VIA MEUCCI, 3, 20091 BRESSO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the discovery and development of novel therapies for diseases of the central and peripheral nervous system. The company's research centers on creating new therapeutic classes to address significant unmet medical needs in difficult-to-treat indications, including Parkinson's disease and schizophrenia. Founded in 1999, Newron leverages its proprietary scientific research and clinical development expertise to advance drug candidates from discovery to commercialization, often through strategic partnerships with other pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-02 07:00
Regulatory News Service
Newron to present new analyses from and updates on its clinical program evaluat…
English 18.0 KB
2025-10-02 02:00
Regulatory News Service
EQS-News: Newron to present new analyses from and updates on its clinical progr…
English 16.4 KB
2025-10-02 02:00
Regulatory News Service
EQS-News: Newron präsentiert neue Analysen und Updates zu seinem klinischen Pro…
German 17.3 KB
2025-09-16 07:00
Earnings Release
Newron veroffentlicht die Ergebnisse des ersten Halbjahres 2025 und gibt ein Up…
German 16.9 KB
2025-09-16 02:00
Earnings Release
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und …
German 15.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron presents H1 2025 results and provides business update
English 24.2 KB
2025-09-16 02:00
Earnings Release
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und g…
German 28.2 KB
2025-09-05 07:00
Regulatory News Service
Newron to present data and updates on its clinical program evaluating evenamide…
English 19.3 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron to present data and updates on its clinical program evaluating…
English 17.6 KB
2025-09-05 02:00
Regulatory News Service
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zu…
German 14.3 KB
2025-08-12 07:00
Regulatory News Service
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
English 17.2 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
English 15.8 KB
2025-08-12 02:00
Regulatory News Service
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
German 18.5 KB
2025-08-11 07:00
Environmental & Social Information
Newron notes the publication of new preclinical research suggesting evenamide a…
English 19.4 KB
2025-08-11 02:00
Regulatory News Service
EQS-News: Newron notes the publication of new preclinical research suggesting e…
English 17.8 KB

Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Biovica International B Logo
Develops blood tests to monitor the efficacy of solid tumor cancer therapies.
Sweden BIOVIC
BL Pharmtech Corp. Logo
Manufactures and distributes health foods, supplements, and cosmetics with bio-pharmaceutical R&D.
South Korea 065170
BOIRON Logo
Global manufacturer of homeopathic medicines for pain relief and flu-like symptoms, sold worldwide.
France BOI
Bosnalijek d.d. Sarajevo Logo
Global manufacturer of drugs for digestive, metabolic, and cardiovascular health.
Bosnia and Herzegovina BSNL
R&D pharma firm developing drugs for CNS disorders, oncology, and metabolic diseases.
South Korea 003000
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea 402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom CNSL
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden CAMX
Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan 4575

Talk to a Data Expert

Have a question? We'll get back to you promptly.